Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. furnished an 8-K to share that it issued a press release on August 13, 2025 reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is attached as Exhibit 99.1, and the company notes that this information is furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.
Jasper Therapeutics reported a net loss of $26.7 million for the quarter and $48.0 million for the six months ended June 30, 2025. Cash and cash equivalents were $39.5 million and total assets declined to $46.5 million from $79.9 million at year-end. Research and development spending rose materially to $21.2 million for the quarter (vs. $11.3 million prior year), driving total operating expenses of $27.1 million.
Management concluded substantial doubt exists about the company's ability to continue as a going concern because existing cash is not sufficient to fund operations for at least twelve months. On July 8, 2025 the company implemented a corporate reorganization, reducing headcount by approximately 50% to focus on its briquilimab mast-cell programs, halting enrollment in the asthma study and discontinuing other programs; estimated severance is approximately $1.9 million. Clinical updates show strong preliminary CSU and CIndU responses but an investigation into a drug product lot is underway and may affect select cohorts.
Kingdon Capital Management, L.L.C. and its founder Mark Kingdon have filed a Schedule 13G with the U.S. SEC disclosing a passive ownership position in Jasper Therapeutics, Inc. (NASDAQ: JSPR).
- Shares owned: 765,000 voting common shares.
- Ownership percentage: 5.1% of Jasper’s outstanding common stock.
- Voting & dispositive power: Both reporting persons hold shared voting and dispositive power over all reported shares; no sole voting or dispositive authority.
- Date of event: 03 July 2025; filing signed 11 July 2025.
- Filing basis: Schedule 13G indicates the stake is for investment purposes only and is not intended to influence control of the issuer.
- Reporting persons: • Kingdon Capital Management, L.L.C. – Delaware investment adviser (Type IA). • Mark Kingdon – U.S. individual (Type HC, IN). All securities are held on behalf of advisory clients of Kingdon Capital.
- Certification: Both filers certify the shares were “not acquired and are not held for the purpose of changing or influencing control.”
This disclosure places Kingdon Capital among Jasper’s significant shareholders, crossing the 5% reporting threshold and potentially increasing institutional visibility in the stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.
The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.
Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).